問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Nuclear Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Neurology

Division of Radiology

更新時間：2023-09-19

顏若芳YEN, RUOH-FANG
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏若芳

List

38Cases

2017-03-01 - 2019-09-30

Phase II

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Condition/Disease

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Test Drug

    SP-02L

Participate Sites
6Sites

Terminated5Sites

2017-01-15 - 2020-02-28

Phase II

An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Condition/Disease

    Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-06-01 - 2018-08-09

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-08-01 - 2024-07-23

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2022-12-21

IIT

Others

Multimodal biomarkers for diagnosis and prognosis in vascular cognitive impairment.

  • Condition/Disease

    Vascular Cognitive Impairment/Alzheimer Disease

  • Test Drug

    11C-PiB

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2020-08-01 - 2025-07-31

IIT

Others

MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in Cerebral Amyloid Angiopathy

  • Condition/Disease

    Cerebral Amyloid Angiopathy(CAA)

  • Test Drug

    (1)11C-PiB (2)18F-T807

Participate Sites
2Sites

Recruiting2Sites

2020-10-01 - 2023-12-31

IIT

Phase II

Establishing 18F-PMPBB3 (APN-1607) PET imaging, genetic and plasma biomarkers for risk identification, disease progression and prognosis of tauopathy related Parkinsonism syndromes

  • Condition/Disease

    Parkinsonism syndromes

  • Test Drug

    18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)

Participate Sites
2Sites

Not yet recruiting2Sites

2018-03-18 - 2024-10-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-07-01 - 2021-08-20

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-09-01 - 2019-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB